InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,305.99
(
0.72%
)
US TECH 100
18,351.80
(
1.13%
)
Dow Jones
39,150.61
(
0.22%
)
Brent Oil
81.95
(
0.78%
)
Bitcoin
68,133.01
(
0.31%
)
Post# of 255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

georgejjl

Send PM Follow Ignore
Followers 138
Posts 22969
Boards Moderated 0
Alias Born 04/08/2004

georgejjl

Re: georgejjl post# 149

Wednesday, 09/22/2021 3:29:24 PM

Wednesday, September 22, 2021 3:29:24 PM

Post# of 255
Cohort 3 of the AXO-Lenti-PD trial is scheduled to start around the end of calendar 2021 or early 2022. Cohort 3 will be 3 times the concentration as the dose given to Cohort 2.

Cohort 2 (n=2 evaluable patients): Positive 6-month data
demonstrating 21-point mean improvement from baseline in
UPDRS III “OFF” score



https://investors.siogtx.com/static-files/53b38274-3d1f-4d98-a157-93e04b94646a

Watch the video below regarding and ProSavin trial from Oxford BioMedica.



Good luck and GOD bless,
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up